Free tool
FAERS Monitor: Liletta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206229 or its brand name (Liletta, Levonorgestrel). Reports on generic versions are filed under their own applications.
Reports
14,329
Serious
3,453
24% of reports
Hospitalization
731
Death reported
60
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device expulsion5,536
- procedural pain1,859
- device dislocation1,163
- drug ineffective626
- off label use546
- uterine perforation543
- uterine spasm392
- nausea295
- pain278
- headache230
- dizziness200
- abdominal pain199
- vaginal haemorrhage198
- uterine haemorrhage193
- embedded device184
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 39 |
| 2006 | 37 |
| 2007 | 27 |
| 2008 | 22 |
| 2009 | 45 |
| 2010 | 64 |
| 2011 | 93 |
| 2012 | 101 |
| 2013 | 45 |
| 2014 | 33 |
| 2015 | 116 |
| 2016 | 657 |
| 2017 | 1,032 |
| 2018 | 476 |
| 2019 | 1,199 |
| 2020 | 1,648 |
| 2021 | 1,420 |
| 2022 | 1,672 |
| 2023 | 2,125 |
| 2024 | 1,282 |
| 2025 | 1,238 |
| 2026 | 919 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,830 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| uterine spasmSignal | 392 | 400.0 | 358.2 | 122,310 |
| device expulsionSignal | 5,536 | 136.9 | 133.9 | 685,100 |
| procedural painSignal | 1,859 | 105.4 | 100.8 | 179,443 |
| uterine perforationSignal | 543 | 100.5 | 92.3 | 50,006 |
| uterine haemorrhageSignal | 193 | 69.6 | 60.3 | 12,395 |
| device dislocationSignal | 1,163 | 40.3 | 38.1 | 43,449 |
| embedded deviceSignal | 184 | 27.8 | 24.0 | 4,635 |
| vaginal haemorrhageSignal | 198 | 6.7 | 5.9 | 956 |
| abdominal pain | 199 | 1.3 | 1.1 | 10 |
| off label use | 546 | 0.9 | 0.8 | 4 |
| drug ineffective | 626 | 0.7 | 0.6 | 88 |
| pain | 278 | 0.7 | 0.6 | 48 |
| dizziness | 200 | 0.6 | 0.5 | 59 |
| nausea | 295 | 0.5 | 0.5 | 115 |
| headache | 230 | 0.5 | 0.5 | 93 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.